Kathleen C. Kobashi, Steven D. Wexner

Canadian Journal of Urology, Vol.28, No.6, pp. 10881-10881, 2021

Abstract This article has no abstract. More >

Leonard G. Gomella

Canadian Journal of Urology, Vol.28, No.6, pp. 10880-10880, 2021

Abstract This article has no abstract. More >

Andrew Salib, J. Ryan Mark

Canadian Journal of Urology, Vol.28, No.1, pp. 10568-10573, 2021

Abstract Prostate cancer is the most common malignancy affecting men. Prostate biopsy remains the key clinical tool for selecting appropriate treatment options. The process of specimen collection and diagnosis is multistep and vulnerable to human error along every stage. Specimen provenance testing (SPT) aims to provide certainty that biopsy results can be trusted when recommending life changing treatments and has emerged as a necessary tool in medicine to counteract human error and specimen contamination. In this study we report our practice’s experience using the Know Error test to verify prostate biopsy specimens. In this study, we… More >

Miguel Rodriguez-Homs¹, Brett Wiesen¹, Mona Rizeq², Colin Randau³, Granville L. Lloyd⁴

Canadian Journal of Urology, Vol.28, No.1, pp. 10565-10567, 2021

Abstract Prostate cancer is rarely metastatic to visceral organs, and even less commonly to the brain. Recent data suggests brain metastasis from prostatic adenocarcinoma occur in 0.16% of patients, and almost universally in the setting of very high-volume disease. We present a man with an abruptly symptomatic brain lesion that developed at a PSA value of 1.5 ng/mL with no other known metastatic disease and required emergent neurosurgical resection. The patient had been initially treated with radiotherapy for Grade Group 4 prostate cancer in 2005 with a long period of PSA suppression. More >

Justin Loloi¹, Susan M. MacDonald²

Canadian Journal of Urology, Vol.28, No.1, pp. 10560-10564, 2021

Abstract Pyodermagangrenosum(PG)isacutaneousinfammatory disorderthatresultsinpainfululcers. IsolatedpenilePG is an exceedingly rare entity that has only been reported in a handful of cases.
This case highlights the course of a 71-year old man with a locally destructive, nonhealing penile ulceration who was ultimately diagnosed with PG. He underwent extensive work up to reach the diagnosis. His disease progression was halted with systemic steroids and Methotrexate.Wepresenthisclinicalcourseandareview oftheliteraturetohighlighttheneedforearlyrecognition of this potentially devastating condition and to outline management options. More >

William W. French¹, Joseph M. Kuebker², Xiang Shu³, Christopher M. Sobey⁴, Ryan S. Hsi²

Canadian Journal of Urology, Vol.28, No.1, pp. 10556-10559, 2021

Abstract Non-obstructive, chronic flank pain in urologic patients can be a challenging problem to manage. In this series, we examined the efficacy of celiac plexus blockade in providing pain relief and reducing opiate use in 14 adult urology patients with non-obstructive flank pain for > 1 year. Demographic, clinical, and procedural variables were collected from the medical record for retrospective analysis. Subjective improvement in pain occurred in 11 individuals (79%), and 5 (50%) were able to reduce their daily morphine equivalent dose (MED). Celiac plexus blockade is a viable option for symptomatic relief in urologic patients More >

Ankur Choksi¹, Shu Wang¹, Michael Phelan¹, Heather Mannuel², Michael Naslund¹, Mohummad Minhaj Siddiqui¹

Canadian Journal of Urology, Vol.28, No.1, pp. 10547-10555, 2021

Abstract Introduction: Complete pathologic response (pT0) at time of cystectomy after neoadjuvant chemotherapy (NAC) has been associated with significantly improved clinical outcomes. The goal of this study is to examine whether race is a predictor of pT0 response to NAC at time of cystectomy.
Materials and methods: We analyzed the records of patients diagnosed with a non-metastatic (M0) muscle-invasive (cT2+) urothelial cell bladder cancer in the National Cancer Database (NCDB) who underwent a cystectomy from 2006 to 2014. The cohort was stratified by whether the patient received NAC prior to cystectomy. Univariate and multivariate logistic regression models were… More >

Rahima Khatun¹, Matthew Galida², Necole M. Streeper²

Canadian Journal of Urology, Vol.28, No.1, pp. 10542-10546, 2021

Abstract Introduction: The opioid epidemic is a growing problem in the United States. There is a high rate of opioid oversupply for treatment of symptomatic nephrolithiasis, partly due to patients being seen by multiple providers. In Pennsylvania, there are efforts to integrate a prescription drug monitoring program (PDMP) within the electronic medical record (EMR). The objectives of this study were to evaluate prescribing practices for opioids for symptomatic nephrolithiasis and the incidence of prescriptions not documented within the EMR.
Materials and methods: Adults who presented for treatment of symptomatic nephrolithiasis were sequentially evaluated from May - October 2017… More >

Jonathan Modai¹, Noam Barda², Yuval Avda¹, Igal Shpunt¹, Dan Leibovici¹, Yaniv Shilo¹

Canadian Journal of Urology, Vol.28, No.1, pp. 10536-10541, 2021

Abstract Introduction: Distal ureteral stones (DUS) are common in patients presenting to the emergency department (ED) with renal colic. The majority of DUS will pass spontaneously and therefore conservative care is common. Follow up is imperative as some of these stones might not pass and potentially lead to complications. The aim of our study was to evaluate the rate of compliance with follow up and to find predictive variables for it.
Materials and methods: We retrospectively surveyed the medical records of all patients who had a non-contrast computed tomography (NCCT) at our ED between 01/03/16 and 31/5/17. We… More >

Bofeng Chen¹, Ruchika Talwar¹, Lauren E. Schwartz², Ryan P. Terlecki³, Thomas J. Guzzo¹, Robert C. Kovell¹

Canadian Journal of Urology, Vol.28, No.1, pp. 10530-10535, 2021

Abstract Introduction: Inter-institutional re-review of prostate needle biopsy (PNBx) material is required at many institutions before definitive treatment, but adds time and cost and may not significantly alter urologic management. We aim to determine the utility of universal PNBx re-review on influencing the decision to recommend definitive local therapy for patients with prostate cancer.
Materials and methods: From 2017-2020, 590 prostate biopsy specimens from outside institutions were re-reviewed at our center for patients considering prostatectomy. Clinical and pathologic characteristics from initial and secondary review were analyzed. Potential for change in treatment candidacy (CTC) was determined by re-diagnosis to… More >